Scandion Oncology Q2: CORIST part 2 readout approaching - Redeye

Redeye comments on Scandion’s Q2 2022 report, coming shortly before the company plans to communicate CORIST part 2 top-line data. We view CORIST part 2 readout as the primary catalyst for the company’s share in H2 2022E. We make some incremental adjustments to our estimates to account for the company’s CORIST expansion and PANTAX phase Ib elongation.

Länk till analysen i sin helhet: https://www.redeye.se/research/853321/scandion-oncology-q2-2022-corist-part-2-readout-approaching?utm_source=finwire&utm_medium=RSS